Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain

British Journal of Pharmacology

Volumn 157, Issue 4, 2009, Pages 645-655

  Zhu, C Z ^a   Mikusa, J P ^a   Fan, Y ^a   Hollingsworth, P R ^a   Pai, M ^a   Chandran, P ^a   Daza, A V ^a   Yao, B B ^a   Dart, M J ^a   Meyer, M D ^a   Decker, M W ^a   Hsieh, G C ^a   Honore, P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cannabinoid; CB 1; CB 2; Mechanical allodynia; Site of action; Skin incision; WIN 55,212 2

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID DERIVATIVE; RADIOLIGAND; RIMONABANT; UNCLASSIFIED DRUG; WIN 55,212 2; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANALGESIC AGENT; BENZOXAZINE DERIVATIVE; CANNABINOID 2 RECEPTOR; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; IN VITRO STUDY; MALE; NONHUMAN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RAT; SKIN INCISION; ANIMAL; BRAIN CORTEX; CELL LINE; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; FOOT; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SPINAL CORD; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; BENZOXAZINES; CELL LINE; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FOOT; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MORPHOLINES; NAPHTHALENES; PAIN, POSTOPERATIVE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; SPINAL CORD;

EID: 70349897566     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00184.x     Document Type: Article

References (64)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ et al. (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870-879. (Pubitemid 47013432)
2. Ahluwalia J, Urban L, Bevan S, Nagy I (2003). Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 17: 2611-2618. (Pubitemid 36819286)
3. Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji RR et al. (2006). Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CBl agonist. Pain 124: 175-183. (Pubitemid 44176209)
4. Brennan TJ, Vandermeulen EP, Gebhart GF (1996). Characterization of a rat model of incisional pain. Pain 64: 493-501.
5. Brennan TJ, Zahn PK, Pogatzki-Zahn EM (2005). Mechanisms of incisional pain. Anesthesiol Clin North America 23: 1-20.
6. Calignano A, La Rana G, Giuffrida A, Plomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281. (Pubitemid 28335039)
7. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.
8. Costa B, Colleoni M, Conti S, Trovato AE, Blanchi M, Sotgiu ML et al. (2004). Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 141: 4-8. (Pubitemid 38241157)
9. Dixon WJ (1980). Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20: 441-462.
10. Dogrul A, Gardell LR, Ma S, Ossipov MH, Porreca F, Lai J (2002). Knock-down of spinal CBl receptors produces abnormal pain and elevates spinal dynorphin content in mice. Pain 100: 203-209. (Pubitemid 35305137)
11. Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F, Guzeldemir E (2003). Topical cannabinoid antinociception: synergy with spinal sites. Pain 105: 11-16. (Pubitemid 37167991)
12. Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME (2004). Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 368: 82-86. (Pubitemid 39178753)
13. Ellington HC, Cotter MA, Cameron NE, Ross RA (2002). The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and nondiabetic rats. Neuropharmacology 42: 966-975.
14. Farquhar-Smith WP, Rice AS (2003). A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factorinduced hyperalgesia. Anesthesiology 99: 1391-1401.
15. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L et al. (2001). The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100. (Pubitemid 32367940)
16. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG (2007). Activation of peripheral cannabinoid CBl and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150: 153-163. (Pubitemid 46160605)
17. Hama A, Sagen J (2007). Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol 204: 454-457. (Pubitemid 46330252)
18. Hohmann AG, Tsou K, Walker JM (1999a). Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao 20: 1132-1136.
19. Hohmann AG, Tsou K, Walker JM (1999b Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol 81: 575-583. (Pubitemid 29264504)
20. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S (2006). A Multicenter Dose-escalation Study of the Analgesic and Adverse Effects of an Oral Cannabis Extract (Cannador) for Postoperative Pain Management. Anesthesiology 104: 1040-1046. (Pubitemid 43755043)
21. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVlI. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202. (Pubitemid 34575709)
22. Johanek LM, Simone DA (2004). Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 109: 432-442.
23. Johanek LM, Simone DA (2005). Cannabinoid agonist, CP 55,940, prevents capsaicin-induced sensitization of spinal cord dorsal horn neurons. J Neurophysiol 93: 989-997.
24. Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, Simone DA (2001). Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 93: 303-315. (Pubitemid 32763187)
25. Kang S, Kim CH, Lee H, Kim DY, Han JI, Chung RK et al. (2007). Antinociceptive synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat formalin test. Anesth Analg 104: 719-725. (Pubitemid 46309899)
26. Kukushkin ML, Igon'kina SI, Churyukanov MV, Churyukanov VV, Bobrov MY, Bezuglov W et al. (2006). Role of cannabinoid receptor agonists in mechanisms of suppression of central pain syndrome. Bull Exp Biol Med 142: 39-42.
27. LaBuda CJ, Koblish M, Little PJ (2005). Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527: 172-174. (Pubitemid 41745165)
28. Lever IJ, Pheby TM, Rice AS (2007). Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity. Br J Pharmacol 151: 292-302.
29. Li J, Daughters RS, Bullis C, Bengiamin R, Stucky MW, Brennan J et al. (1999). The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 81: 25-33. (Pubitemid 29199898)
30. Lichtman AH, Cook SA, Martin BR (1996). Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276: 585-593. (Pubitemid 126660496)
31. Lim G, Sung B, Ji RR, Mao J (2003). Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105: 275-283. (Pubitemid 37162497)
32. Martin WJ, Hohmann AG, Walker JM (1996). Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 16: 6601-6611.
33. Martin WJ, Loo CM, Basbaum AI (1999). Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 82: 199-205.
34. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H et al. (2006). Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126: 102-114. (Pubitemid 44781351)
35. Nackley AG, Suputa RL 2nd, Hohmann AG (2003). A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 117: 659-670.
36. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462. (Pubitemid 44394908)
37. Pascual D, Goicoechea C, Suardiaz M, Martin MI (2005). A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118: 23-34. (Pubitemid 41566582)
38. Paxinos P, Watson C (1982). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
39. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611.
40. Piomelli D (2005). The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6: 672-679. (Pubitemid 40904037)
41. Pogatzki EM, Gebhart GF, Brennan TJ (2002). Characterization of Adelta- and C-fibers innervating the plantar rat hindpaw one day after an incision. J Neurophysiol 87: 721-731.
42. Raffa RB, Stone DJ Jr, Hipp SJ (1999). Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice. Neurosci Lett 263: 29-32.
43. Richardson JD, Aanonsen L, Hargreaves KM (1998a). Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345: 145-153.
44. Richardson JD, Kilo S, Hargreaves KM (1998b). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111-119. (Pubitemid 28254862)
45. Romero-Sandoval A, Eisenach JC (2007). Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106: 787-794. (Pubitemid 46555623)
46. Rukwied R, Watkinson A, McGlone F, Dvorak M (2003). Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102: 283-288. (Pubitemid 36369307)
47. Sokal DM, Elmes SJ, Kendall DA, Chapman V (2003). Intraplantar Injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 45: 404-411.
48. Strangman NM, Walker JM (1999). Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 82: 472-477.
49. Tsou K, Lowitz KA, Hohmann AG, Martin WJ, Hathaway CB, Bereiter DA et al. (1996). Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 70: 791-798. (Pubitemid 26009816)
50. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neurosience 83: 393-411. (Pubitemid 28062631)
51. Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I (2004). The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 371: 167-170. (Pubitemid 39440764)
52. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658-672. (Pubitemid 40462406)
53. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2006). Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83: 1310-1322. (Pubitemid 43668014)
54. Walker JM, Hohmann AG (2005). Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 509-554.
55. Wang YX, Pettus M, Gao D, Phillips C, Scott Bowersox S (2000). Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 84:151-158. (Pubitemid 30074216)
56. Wegener N, Kuhnert S, Thuns A, Roese R, Koch M (2008). Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. Psychopharmacology (Berl) 198: 375-385.
57. Welch SP, Thomas C, Patrick GS (1995). Modulation of cannabinoidinduced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272: 310-321.
58. Yaksh TL, Rudy TA (1976). Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17: 1031-1036.
59. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV et al. (2008). In vitro and in vivo characterization of A-796260: a selective cannabinoid CB(2) receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153: 390-401.
60. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK et al. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149: 145-154. (Pubitemid 44360095)
61. Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y et al. (2003). Topical cannabinoid enhances topical morphine antinociception. Pain 105: 303-308. (Pubitemid 37162500)
62. Yoon MH, Choi JI (2003). Pharmacologic interaction between cannabinoid and either Clonidine or neostigmine in the rat formalin test. Anesthesiology 99: 701-707.
63. Zahn PK, Brennan TJ (1998). Intrathecal metabotropic glutamate receptor antagonists do not decrease mechanical hyperalgesia in a rat model of postoperative pain. Anesth Analg 87: 1354-1359. (Pubitemid 28549505)
64. Zhu CZ, Hsieh G, Ei-Kouhen O, Wilson SG, Mikusa JP, Hollingsworth PR et al. (2005). Role of central and peripheral mGluR5 receptors in post-operative pain in rats. Pain 114: 195-202. (Pubitemid 40279101)